The Osteosarcoma Project sponsored by BTG Specialty Pharmaceuticals

This episode is sponsored by BTG Speciality Pharmaceuticals. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications. Their drug, Voraxaze, is for high-dose methotrexate toxicity. Corrie Painter is the Deputy Director of Count Me In and is a research scientist at the Broad Institute of MIT and Harvard. A trained cancer researcher with a Ph.D. in biochemistry, she completed her postdoctoral work in cancer immunology, focused on melanoma. In 2010, Painter was diagnosed with angiosarcoma. She has combined her cancer advocacy and scientific background to engage with patients in order to build and carry out patient-partnered genomics studies. She is also the co-founder of Angiosarcoma Awareness Inc. Taylor Cusher is a clinical project manager with Count Me In at the Broad Institute of MIT and Harvard. In this role she manages several patient-partnered research studies that generate and share clinical, genomic, and patient-reported data for rare cancers. Prior to joining the Broad Institute, Cusher led programs on patient access to health data and patient engagement in medical R&D at FasterCures, a center of the Milken Institute. In these roles, her passion for enhancing connection and community at the intersection of patients and research is at the forefront of her work. Cusher holds a BS in kinesiology from the University of Massachusetts Amherst and a Master's degree in public health from the George Washington University.